Table 1: Immunosuppressive conditions with relative risk for TaGVHD.

At risk groups of patients

(1) Autologous bone marrow/stem cell transplant recipients
(2) Allogeneic bone marrow/stem cell transplantrecipients
(3) Hodgkin’s disease
(4) B-cell malignancies (non-Hodgkin’s lymphoma, multiple  myeloma, Waldenstrom’s macroglobulinemia, ALL)
(5) Fludarabine, cladribine therapy
(6) Directed donations from blood relatives
(7) HLA matched platelets
(8) Congenital immunodeficiency disorders (SCID, Wiskott-Aldrich)
(9) Intrauterine transfusions
(10) Granulocyte transfusions in infants